ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
Mitral annular disjunction in Marfan syndrome: a multicenter cardiovascular magnetic resonance study.
Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on the prevalence of mitral annular disjunction (MAD) in Marfan syndrome (MFS) based on cardiovascular magnetic resonance (CMR) is sparse. The purpose of this study was to assess prevalence, extent, and distribution of MAD in MFS using CMR and to examine its association with left heart parameters, aortic dimensions, and cardiovascular events.
methodsThis retrospective multicenter study included CMR studies of patients treated for MFS at four tertiary care medical centers with a (likely) pathogenic fibrillin-1 gene variant. Two radiologists (5 and 8 years of experience in CMR) evaluated datasets for MAD (at 4 points around the annulus, including measurement of extent) and mitral valve prolapse (MVP). Further assessment comprised volumetric and functional analysis of the left ventricle (LV), left atrial size, and aortic root diameters. Cardiovascular events included aortic (aortic surgery or aortic dissection), arrhythmic (sustained ventricular tachycardia or sudden cardiac death), and mitral events (mitral valve surgery, MVS).
resultsAmong 91 patients [(28.9±14.0 years, 47.3% female (n = 43/91)]81.3% (n = 74/91) had MAD (extent: 6.1±2.6 mm). MAD was mostly found at the inferior insertion (72.5% of patients, n = 66/91) and usually affected all sites (39.6% of patients, n = 36/91). Left heart parameters and aortic dimensions did not differ between MAD and no MAD groups (P>0.05). MAD extent and localizations showed significant correlations with LV dilatation (e.g., inferior MAD: r=0.62 for end-diastolic volume index), decreased LV ejection fraction (e.g., anterolateral MAD: r=-0.46), and MVP (e.g., MAD distance: r=0.83), which was found in 44.6% of patients (n = 33/74) with MAD while only affecting 11.8% (n = 2/17) without MAD (P=0.017). Based on receiver operating characteristic analysis for the prediction of MVP prevalence, a threshold of 7.1 mm MAD extent was identified as the optimal cut-off value (sensitivity: 77.1%, specificity: 89.3%). Additionally, subgroup analysis applying different thresholds of MAD extent revealed a significantly larger displacement of MVP and LV volumes as well as higher aortic root z scores for a threshold of ≥8 mm. After a mean follow-up of 4.0±3.0years, cardiovascular events (aortic: n=13/91 [14.3%], arrhythmic: n= 2/91 [2.2%], and mitral: n=2/91 [2.2%] of patients) did not differ significantly (all P>0.05) between no MAD and MAD groups regardless of applied thresholds although MVS was observed exclusively in patients with MAD.
conclusionThe high prevalence, large extent, and predominantly pan-annular distribution of MAD suggest a systemic annular pathology in MFS. Overall presence of MAD was not associated with changes to left heart parameters, aortic dimensions, and cardiovascular events. However, MAD, taking into account its extent and affected insertion sites, could serve as a potential marker of disease progression given the shown association of localizations and distance with LV dysfunction and remodeling as well as aortic enlargement and the formation of MVP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.